Lexiscan, Rapiscan (regadenoson) is a small molecule pharmaceutical. Regadenoson was first approved as Lexiscan on 2008-04-10. It has been approved in Europe to treat myocardial perfusion imaging. The pharmaceutical is active against adenosine receptor A2a. In addition, it is known to target adenosine receptor A1, adenosine receptor A2b, and adenosine receptor A3. Lexiscan's patents are valid until 2027-02-02 (FDA).
|Indication||myocardial perfusion imaging|
|Drug Class||Adenosine A receptor agonists|